Medicure Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. With cardiovascular medicine representing the largest pharmaceutical sector (annual global sales over $70 billion), Medicure aims to make a global impact on cardiovascular disease and stroke by reducing deaths, improving the quality of life and serving the unmet needs of people who suffer from cardiovascular disease and stroke.
Medicure’s Product Pipeline Includes:
• AGGRASTAT
o Approved by the FDA for treatment of Acute Coronary Syndrome
o Reduces Death and MI in high risk patients with ACS by 41%
o Competes in the $500 million dollar annual GP llb/llla inhibitor
market
o Strong record of clinical efficacy and safety
o Lowest price GP llb/lla
• MC- 1 CHRONIC
o Naturally occurring small molecule
o Extensive clinical history and excellent safety profile
o Cardiovascular and metabolic clinical opportunities; lipids, diabetes,
and hypertension
o Non-cardiovascular clinical opportunity; neurological disorders
• ANTITHROMBOTIC PROGRAM
o Dual acting anti-coagulants and platelet aggregation inhibitors
o Library of proprietary small molecules
o Preclinical lead candidate: MC-45308
